Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 126 for:    lymphedema | Recruiting, Not yet recruiting, Available Studies

Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE) (AdeLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03658967
Recruitment Status : Recruiting
First Posted : September 6, 2018
Last Update Posted : April 11, 2019
Sponsor:
Information provided by (Responsible Party):
Herantis Pharma Plc.

Brief Summary:
This study evaluates the efficacy of Lymfactin® in patients with secondary lymphedema associated with the treatment of breast cancer by comparing the effects of active study treatment Lymfactin® to placebo. The study product will be administered in combination with a surgical lymph node transfer operation. In addition, the safety and tolerability of the Lymfactin® treatment will be evaluated.

Condition or disease Intervention/treatment Phase
Secondary Lymphedema Drug: Lymfactin® (1x10E11 vp) Drug: Placebo Phase 2

Detailed Description:

This is a Phase II, double-blind, placebo-controlled, multi-centre clinical study, in which 40 patients with breast cancer associated secondary lymphedema will be randomized 1:1 either to Lymfactin® (1 x 10E11 viral particles, vp) or placebo (0.9% physiological saline) group.

The study product (Lymfactin® or placebo solution) will be administered as a single dose in a volume of two (2) mL, by ex vivo perinodal injection into the fat pad of a flap of tissue containing lymph nodes from the patient's own abdominal wall or the groin area. This flap of tissue will then be surgically implanted into the axillary region of the affected arm. This treatment with the study product is performed in combination with a surgical lymph node transfer, in conjunction with or without breast reconstruction surgery.

Patients will be followed-up for efficacy and safety according to a specified schedule up to 5 years post-treatment.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-blind, placebo-controlled, randomized
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind
Primary Purpose: Treatment
Official Title: Phase 2, Double-Blind, Placebo-Controlled, Randomized Efficacy, Safety and Tolerability Study of Lymfactin in Combination With Surgical Lymph Node Transfer To Patients With Secondary Lymphedema Associated With the Treatment of Breast Cancer
Actual Study Start Date : June 7, 2018
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphedema

Arm Intervention/treatment
Active Comparator: Lymfactin® (1x10E11 vp)
Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
Drug: Lymfactin® (1x10E11 vp)
Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
Other Name: LX-1101, AdAptVEGF-C adenoviral vector

Placebo Comparator: Placebo (0.9% physiological saline)
Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
Drug: Placebo
Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
Other Name: 0.9% Physiological saline




Primary Outcome Measures :
  1. Measurement of the volume of the arms [ Time Frame: 24 Months ]
    Changes in the volume of the affected arm and comparison to the unaffected arm.

  2. Measurement of the lymphatic flow of the affected arm by quantitative lymphoscintigraphy (99Tc-nanocolloid clearance rate with calculation of transport index). [ Time Frame: 24 Months ]
    Assessment of the changes in the lymphatic flow.

  3. Questionnaire according to the Lymphedema Quality of Life Inventory (LQOLI) [ Time Frame: 24 Months ]
    Assessment of changes in the quality of life using Lymphedema Quality of Life Inventory (LQOLI) in which the patients assess how their lymphedema is affecting the activities of daily living. LQOLI consists of three dimensions: Physical, psychosocial and practical, which are reported separately as the mean score of that part. Each part of the LQOLI is scored from 0 to 3, where score 0 means "no impact", 1 means "a little bit impact", 2 means "somewhat impact" and score 3 means "significant impact" on the quality of life of the patient, the smaller score thus being the better.


Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 24 Months ]
    Adverse Events as assessed by CTCAE v4.0 to evaluate the safety profile after administration of Lymfactin.

  2. CT scan of chest and abdomen [ Time Frame: 60 Months ]
    Changes in CT scans of chest and abdomen in order to detect malignancies.

  3. Lymfactin genome copy number in blood [ Time Frame: 30 Days ]
    Changes in Lymfactin genome copy number in blood.

  4. Lymfactin genome copy number in wound secretion [ Time Frame: 7 Days ]
    Changes in Lymfactin genome copy number in wound secretion.

  5. Formation of anti-Lymfactin antibodies [ Time Frame: 12 Months ]
    Changes in anti-Lymfactin antibody titer in blood.

  6. Systemic concentration of vascular endothelial growth factor C (VEGF-C) [ Time Frame: 30 Days ]
    Changes in the VEGF-C concentration in blood.


Other Outcome Measures:
  1. Optional evaluation of the anatomy and functionality of lymphatic vessels by MRI lymphangiography [ Time Frame: 24 Months ]
    Changes in anatomy and functionality of lymphatic vessels by newly developed MRI lymphangiography and comparison of the correlation of the method to the already established lymphoscintigraphy in the assessment of lymphedema.

  2. Percentage Water Content (PWC) measurement of water content and edema [ Time Frame: 24 months ]
    Changes in PWC measurement of water content and edema in affected arm and comparison to the unaffected arm.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female or male patients with secondary lymphedema associated with the treatment of breast cancer and

    • Has undergone sentinel lymph node biopsies and/or lymph node resection in the axilla on the affected side of their breast cancer with initial N1-N2a staging and lymph node metastasis in ≤ 9 axillary lymph nodes.
    • Requires garment use as a compression treatment for the lymphedema in the affected arm.
    • Has the volume of the affected arm at least 10% greater than the unaffected arm following 7 days without compression garment.
    • Has the presence of pitting edema in the affected arm without compression garment.
    • Has had lymphedema for less than 5 years.
  2. No evidence of recurrent or active breast cancer for at least 2 years after the breast cancer surgery and/or the end of chemotherapy and/or radiotherapy (excluding endocrine treatment).
  3. Patient understands and voluntarily signs the written informed consent prior to any screening procedure.
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  5. Body Mass Index (BMI) between 18 and 32 inclusive.
  6. Positron Emission Tomography-Computed Tomography (PET CT) scan of the chest and the abdomen within 45 days before the study treatment without signs of active breast cancer or any other malignancy.
  7. Adequate hematologic and end-organ function.

    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limit of normal (ULN)
    • Bilirubin ≤ 1.5 x ULN (except in patients with previously documented Gilbert's syndrome, in which case total bilirubin ≤ 3 x ULN)
    • International Normalized ratio (INR) and Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN (for patients requiring therapeutic anticoagulation therapy, a stable INR ≤ 2,5)
    • Serum creatinine ≤ 1,5 x ULN or creatinine clearance ≥ 50 ml/min
    • Absolute neutrophil count (ANC) ≥ 1,5 E9/l
    • Platelet count ≥ 100 E9/l
    • Hemoglobin ≥ 100 g/l
  8. Willingness to comply with scheduled visits, laboratory assessments, and other study-related procedures due to the regulatory requirements related to gene based therapies.
  9. Non-smoker or willing to stop smoking or use of nicotine-containing products for at least 4 weeks prior to the study entry.
  10. Negative urine pregnancy test (only patients with childbearing potential) at screening and use of adequate contraceptive measures from screening until six months after the study treatment administration:

    • A patient with childbearing potential should be using a reliable contraception method: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone releasing system (IUS), bilateral tubal occlusion, vasectomised partner or sexual abstinence defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.
    • A male patient is not allowed to donate sperm.
    • A patient with no current heterosexual relationship may be included according to the judgement of the Investigator.
    • For patient in postmenopausal state neither contraception nor a pregnancy test is required. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy.
    • For permanently sterile patient neither contraception nor a pregnancy test is required. A permanently sterile is defined by history of hysterectomy, bilateral salpingectomy or bilateral oophorectomy.

Exclusion Criteria:

  1. Diagnosed for T4 and/or N2b/N3 stage breast cancer at the time of the original diagnosis.
  2. Evidence (clinical, laboratory or imaging) or history of a neoplasm other than breast cancer (except basal cell carcinoma or cervical in situ carcinoma).
  3. Diagnosed for metastatic breast cancer.
  4. Pregnancy, lactation or a positive or indeterminate pregnancy test.
  5. Current treatment with Cyclooxygenase-2 (COX-2) inhibitors should be interrupted from 2 weeks prior until 4 weeks post-treatment.
  6. Previous treatment with, or participation in a trial of a gene therapy product.
  7. Participation in a clinical trial, which has included interventions in the preceding 6 months or will involve future interventions. Participation in a non-interventional clinical trial, or in a non-interventional follow-up of any clinical trial, does not make the patient inappropriate for the entry into this study.
  8. Current treatment with immunosuppressive drugs.
  9. Current history of drug abuse, including nicotine-containing products, or alcohol abuse.
  10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
  11. History of hepatic dysfunction, cirrhosis, or hepatitis.
  12. Allergy to any ingredients of the Lymfactin® solution for injection.
  13. Other concurrent severe acute and/or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with the study participation or study drug administration, that would, in the Investigator's judgement, affect the patient's ability to follow study-related procedures, or that may interfere with the interpretation of study results and would make the patient inappropriate for the entry into this study.
  14. Doubtful availability, in the opinion of the Investigator, to complete the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03658967


Contacts
Layout table for location contacts
Contact: Outi Lahdenperä, MD, PhD +358(0)405113194 outi.lahdenpera@herantis.com

Locations
Layout table for location information
Finland
Töölö Hospital, Department of Plastic Surgery Recruiting
Helsinki, Finland
Contact: Sinikka Suominen, MD, PhD         
Tampere University Hospital, Department of Plastic Surgery Recruiting
Tampere, Finland
Contact: Juha Kiiski, MD, PhD         
Turku University Hospital, Department of Plastic Surgery Recruiting
Turku, Finland
Contact: Pauliina Hartiala, MD, PhD         
Sweden
Karolinska University Hospital, Department of Reconstructive Plastic Surgery Recruiting
Stockholm, Sweden
Contact: Martin Halle, MD, PhD         
Uppsala University Hospital, Department of Plastic Surgery Recruiting
Uppsala, Sweden
Contact: Maria Mani, MD, PhD         
Sponsors and Collaborators
Herantis Pharma Plc.
Investigators
Layout table for investigator information
Principal Investigator: Anne Saarikko, MD, PhD Helsinki University Central Hospital
Principal Investigator: Maria Mani, MD, PhD Uppsala University Hospital

Layout table for additonal information
Responsible Party: Herantis Pharma Plc.
ClinicalTrials.gov Identifier: NCT03658967     History of Changes
Other Study ID Numbers: HP-LY-CL-2063
2017-004443-20 ( EudraCT Number )
First Posted: September 6, 2018    Key Record Dates
Last Update Posted: April 11, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Herantis Pharma Plc.:
Lymphedema
Breast cancer
Adenoviral vector
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Lymphedema
Neoplastic Processes
Neoplasms
Pathologic Processes
Lymphatic Diseases